Varying additive effects of bromocriptine with two somatostatin analogs in cultures of GH-secreting adenomas

Hormone and Metabolic Research

Volumn 34, Issue 8, 2002, Pages 435-440

  Balsa, J Antonio ^a   Varela, C ^a   Lucas, T ^b   Garcia Uria J ^b   Barcelo B ^b   Sancho Rof, J M ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

Acromegaly; Bromocriptine; Somatostatin Analogs

Indexed keywords

ANGIOPEPTIN; BROMOCRIPTINE; CYCLIC AMP; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; OCTREOTIDE; PROLACTIN; QUINAGOLIDE; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADULT; AGED; ARTICLE; CELL CULTURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GROWTH HORMONE RELEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOPHYSIS ADENOMA; HYPOPHYSIS TUMOR; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; TRANSSPHENOIDAL SURGERY; TREATMENT OUTCOME;

ACROMEGALY; ADENOMA; ADULT; AGED; BROMOCRIPTINE; CYCLIC AMP; DOPAMINE AGONISTS; FEMALE; HORMONE ANTAGONISTS; HORMONES; HUMAN GROWTH HORMONE; HUMANS; MALE; MIDDLE AGED; OCTREOTIDE; PEPTIDES, CYCLIC; PITUITARY NEOPLASMS; SEX CHARACTERISTICS; SOMATOSTATIN; TUMOR CELLS, CULTURED;

EID: 0036674606     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-33601     Document Type: Article

References (24)

1. Current treatment guidelines for acromegaly
2. A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201-995, bromocriptine, and combination of both drugs
3. Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: A comparison with bromocriptine
4. Dynamics of the acute effects of octeotride, bromocriptine and both drugs in combination on growth hormone secretion in acromegaly
5. A comparison of octreotide, bromocriptine, or a combination of both drugs in acromegaly
6. Treatment with octreotide and bromocriptine in patients with acromegaly: An open pharmacodynamic interaction study
7. CV 205-502 treatment in therapy-resistant acromegalic patients
8. A comparison between the effects of SMS 201-995, bromocriptine, and a combination of both drugs on hormone release by the cultured pituitary tumour cells of acromegalic patients
9. Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr1-5)
10. Molecular biology of somatostatin receptors
11. Clinical, biochemical, and morphological correlates in patients bearing growth hormone-secreting pituitary tumors with or without constitutively active adenylyl ciclase
12. Biochemical characteristics of human pituitary somatotropinomas with and without gsp mutations: In vitro cell culture studies
13. Ion channels and the signal transduction pathways in the regulation of growth hormone secretion
14. Intracellular calcium ion responses to somatostatin in cells from human somatotroph adenomas
15. Mammosomatotroph adenoma causing gigantism in an 8-year-old boy: A possible pathogenetic mechanism
16. + channels by dopamine in human GH-producing cells
17. Differential transduction of dopamine signal in different subtypes of human growth hormone secreting adenomas
18. Preoperative treatment of growth hormone pituitary adenomas with lanreotide
19. Effectiveness of slow-release lanreotide in previously operated and untreated patients with GH-secreting pituitary macroadenoma
20. Protein measurement with folin phenol reagents
21. Comparison of the sensitivity of growth hormone secretion to somatostatin in vivo and in vitro in acromegaly
22. Prognostic and therapeutic consequences of Gsα mutations in somatotroph adenomas
23. Somatostatin receptor subtype 2 and 5 in human GH-secreting pituitary adenomas: Analysis of gene sequence and mRNA expression
24. Receptors for dopamine and somatostatin: Formation of hetero-oligomers with enhanced functional activity